WCH Stock Analysis: Wacker Chemie | XETRA
Specialty Chemicals | XETRA, Germany | Market Cap: 4.392m EUR | 12M Return: 34.7% | DE000WCH8881 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.48M
Qual. Beats: 0
Rev. Trend: -90.3%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Wacker Chemie AG is a German specialty chemicals manufacturer headquartered in Munich, founded in 1914 and listed on the XETRA exchange. The company operates through four business segments: Silicones, Polymers, Biosolutions, and Polysilicon, producing a wide range of chemical products including siloxanes, silicone elastomers, dispersible polymer powders, pharmaceutical proteins, cyclodextrins, and hyperpure polysilicon. Its products serve customers across automotive, construction, chemical, semiconductor, consumer goods, medical technology, pharmaceutical, and photovoltaic industries, with sales reaching Europe, Asia, the Americas, and other international markets.
The company also operates e-business platforms and support services, and exports its products globally. Wacker Chemie AG is a subsidiary of Dr. Alexander Wacker Familiengesellschaft mbH, reflecting its founding familys continued controlling stake.
The polysilicon segment supplies hyperpure silicon used as a critical raw material in the semiconductor and solar photovoltaic industries, linking Wackers business to both electronics and renewable energy supply chains. Its biosolutions segment produces bioengineered pharmaceutical proteins, vaccines, and food additives, giving the company exposure to the pharmaceutical and life sciences value chain alongside its traditional specialty chemicals operations.
- Chinese polysilicon oversupply pressures WCH segment pricing and margins
- European natural gas costs weigh on silicones margin recovery
- Solar PV and semiconductor polysilicon demand tracks cyclical recovery
| Net Income: -432.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 11.02 > 1.0 |
| NWC/Revenue: 47.60% < 20% (prev 42.76%; Δ 4.83% < -1%) |
| CFO/TA 0.08 > 3% & CFO 740.4m > Net Income -432.9m |
| Net Debt (1.04b) to EBITDA (547.3m): 1.91 < 3 |
| Current Ratio: 2.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.8m) vs 12m ago 27.18% < -2% |
| Gross Margin: 14.08% > 18% (prev 16.07%; Δ -1.99% > 0.5%) |
| Asset Turnover: 63.00% > 50% (prev 64.28%; Δ -1.28% > 0%) |
| Interest Coverage Ratio: 0.36 > 6 (EBIT TTM 61.7m / Interest Expense TTM 171.2m) |
| A: 0.30 (Total Current Assets 4.20b - Total Current Liabilities 1.57b) / Total Assets 8.72b |
| B: 0.40 (Retained Earnings 3.49b / Total Assets 8.72b) |
| C: 0.01 (EBIT TTM 61.7m / Avg Total Assets 8.76b) |
| D: 0.89 (Book Value of Equity 4.02b / Total Liabilities 4.54b) |
| Altman-Z'' = 4.26 = AA |
| DSRI: 1.10 (Receivables 897.0m/836.4m, Revenue 5.52b/5.66b) |
| GMI: 1.14 (GM 16.07% / 14.08%) |
| AQI: 0.65 (AQ_t 0.12 / AQ_t-1 0.19) |
| SGI: 0.98 (Revenue 5.52b / 5.66b) |
| TATA: -0.13 (NI -432.9m - CFO 740.4m) / TA 8.72b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of October 04, 2026, the stock is trading at EUR 88.90 with a total of 39,060 shares traded. Over the past week, the price has changed by +1.66%, over one month by -5.38%, over three months by -2.09% and over the past year by +34.72%.
Current recommended Stop Loss: 84.60 (which is 4.8% or 1.5 ATR below the current price).
Wacker Chemie has no consensus analysts rating.
P/E Forward = 21.9298
P/S = 0.796
P/B = 1.0922
P/EG = 5.1721
Revenue TTM = 5.52b EUR
EBIT TTM = 61.7m EUR
EBITDA TTM = 547.3m EUR
Long Term Debt = 1.93b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 363.2m EUR (from shortTermDebt, last quarter)
Debt = 2.62b EUR (from shortLongTermDebtTotal, last quarter) + Leases 323.0m
Net Debt = 1.04b EUR (calculated: Debt 2.62b - CCE 1.57b)
Enterprise Value = 5.44b EUR (4.39b + Debt 2.62b - CCE 1.57b)
Interest Coverage Ratio = 0.36 (Ebit TTM 61.7m / Interest Expense TTM 171.2m)
EV/FCF = 17.22x (Enterprise Value 5.44b / FCF TTM 315.8m)
FCF Yield = 5.81% (FCF TTM 315.8m / Enterprise Value 5.44b)
FCF Margin = 5.72% (FCF TTM 315.8m / Revenue TTM 5.52b)
Net Margin = -7.84% (Net Income TTM -432.9m / Revenue TTM 5.52b)
Gross Margin = 14.08% ((Revenue TTM 5.52b - Cost of Revenue TTM 4.74b) / Revenue TTM)
Gross Margin QoQ = 16.85% (prev 15.63%)
Tobins Q-Ratio = 0.62 (Enterprise Value 5.44b / Total Assets 8.72b)
Interest Expense / Debt = 6.54% (Interest Expense 171.2m / Debt 2.62b)
Taxrate = 6.78% (22.2m / 327.4m)
NOPAT = 57.5m (EBIT 61.7m * (1 - 6.78%))
Current Ratio = 2.67 (Total Current Assets 4.20b / Total Current Liabilities 1.57b)
Debt / Equity = 0.65 (Debt 2.62b / totalStockholderEquity, last quarter 4.02b)
Debt / EBITDA = 1.91 (Net Debt 1.04b / EBITDA 547.3m)
Debt / FCF = 3.31 (Net Debt 1.04b / FCF TTM 315.8m)
Total Stockholder Equity = 3.89b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.94% (Net Income -432.9m / Total Assets 8.72b)
RoE = -11.14% (Net Income TTM -432.9m / Total Stockholder Equity 3.89b)
RoCE = 1.06% (EBIT 61.7m / Capital Employed (Equity 3.89b + L.T.Debt 1.93b))
RoIC = 0.79% (NOPAT 57.5m / Invested Capital 7.24b)
WACC = 7.61% (E(4.39b)/V(7.01b) * Re(8.52%) + D(2.62b)/V(7.01b) * Rd(6.54%) * (1-Tc(0.07)))
Discount Rate = 8.52% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 16.59 | Cagr: 0.15%
[DCF] Terminal Value 75.44% ; FCFF base≈315.8m ; Y1≈317.1m ; Y5≈335.9m
[DCF] Fair Price = 84.13 (EV 5.22b - Net Debt 1.04b = Equity 4.18b / Shares 49.7m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.06 | # QB: 0
Revenue Correlation: -90.30 | Revenue CAGR: -6.75% | SUE: 0.04 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.27 | Chg30d=+80.78% | Revisions=+25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.91 | Chg30d=N/A | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=1.52 | Chg30d=+0.00% | Revisions=+50% | GrowthEPS=+124.4% | GrowthRev=+4.1%
EPS next Year (2027-12-31): EPS=3.08 | Chg30d=+37.61% | Revisions=+40% | GrowthEPS=+103.3% | GrowthRev=+3.0%
[Analyst] Revisions Ratio: +70% (up=7, down=0)